Zymeworks, Inc. (ZYME)
25.14
-0.70
(-2.71%)
USD |
NASDAQ |
Nov 18, 12:44
Zymeworks Net Income (Quarterly) : 173.70M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 173.70M |
| June 30, 2026 | -45.02M |
| March 31, 2026 | -44.16M |
| December 31, 2025 | -41.21M |
| September 30, 2025 | -19.60M |
| June 30, 2025 | 2.317M |
| March 31, 2025 | -22.64M |
| December 31, 2024 | -23.51M |
| September 30, 2024 | -29.85M |
| June 30, 2024 | -37.69M |
| March 31, 2024 | -31.65M |
| December 31, 2023 | -14.48M |
| September 30, 2023 | -28.69M |
| June 30, 2023 | -51.15M |
| March 31, 2023 | -24.35M |
| December 31, 2022 | 309.43M |
| September 30, 2022 | -47.85M |
| June 30, 2022 | -64.62M |
| March 31, 2022 | -72.62M |
| December 31, 2021 | -39.15M |
| September 30, 2021 | -60.58M |
| June 30, 2021 | -67.52M |
| March 31, 2021 | -44.59M |
| December 31, 2020 | -37.89M |
| September 30, 2020 | -72.56M |
| Date | Value |
|---|---|
| June 30, 2020 | -38.96M |
| March 31, 2020 | -31.14M |
| December 31, 2019 | -72.24M |
| September 30, 2019 | -30.48M |
| June 30, 2019 | -29.08M |
| March 31, 2019 | -13.64M |
| December 31, 2018 | 9.273M |
| September 30, 2018 | -18.75M |
| June 30, 2018 | -5.874M |
| March 31, 2018 | -21.20M |
| December 31, 2017 | 32.73M |
| September 30, 2017 | -16.24M |
| June 30, 2017 | -10.97M |
| March 31, 2017 | -15.93M |
| December 31, 2016 | -11.28M |
| September 30, 2016 | -12.40M |
| June 30, 2016 | -7.423M |
| March 31, 2016 | -2.712M |
| December 31, 2015 | -7.949M |
| September 30, 2015 | -5.812M |
| June 30, 2015 | -4.519M |
| March 31, 2015 | -0.89M |
| December 31, 2014 | -3.223M |
| September 30, 2014 | -3.514M |
| June 30, 2014 | -3.451M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 4.207B |
| Faeth Therapeutics, Inc. | -20.40M |
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 256.46M |
| Total Expenses (Quarterly) | 82.76M |
| EPS Diluted (Quarterly) | 2.278 |
| Enterprise Value | 2.403B |
| Gross Profit Margin (Quarterly) | 99.01% |
| Profit Margin (Quarterly) | 67.73% |
| Earnings Yield | 2.08% |
| Operating Earnings Yield | 2.35% |
| Normalized Earnings Yield | 2.089 |